Results 131 to 140 of about 349,007 (339)

Angina and hypertension [PDF]

European Heart Journal Supplements, 2019
Athanasios J. Manolis, Manolis S. Kallistratos, Leonidas E. Poulimenos   +2 more
openaire   +3 more sources

Ludwig's Angina

Internal Medicine, 2021
Michitoshi Araki, Hirofumi Yoshida, Masanori Kawataki   +2 more
openaire   +4 more sources

Vincent's angina [PDF]

The Laryngoscope, 1919
n ...
openaire   +2 more sources

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Angina Pectoris Prevalence and Sick Leave Burden 1 Year After Myocardial Infarction With Nonobstructive Coronary Arteries

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Symptom burden and disease effects following myocardial infarction with nonobstructive coronary arteries (MINOCA) are not well studied. We aimed to evaluate the prevalence of angina pectoris, sick leave, and quality‐of‐life levels 1 year after
Kerstin Welén Schef, Per Tornvall, Bertil Lindahl, Anna M. Nordenskjöld, Tomas Jernberg   +4 more
doaj   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

The mechanism of action of metabolic cytoprotector trimetazidine in acute ischemia-reperfusion injury

КардиоСоматика, 2014
The review presents, as the classical data on the mechanism of action of metabolic cytoprotector trimetazidine in acute ischemia/reperfusion injury associated with a partial inhibition of the oxidation of long chain fatty acids and increased metabolism ...
M. G Glezer, E. I Astashkin, M. V Novikova   +2 more
doaj  

Nitroglycerin and Other Nitrites in the Treatment of Angina Pectoris [PDF]

, 1958
Joseph E.F. Riseman, George E. Altman, Sidney Koretsky   +2 more
openalex   +1 more source

Poor cardiovascular outcomes of underweight abdominal obesity in the entire population of newly diagnosed heart failure

ESC Heart Failure, EarlyView.
Abstract Aims Body mass index (BMI) has been widely used as a simple tool for predicting cardiovascular risk. Here we aimed to analyse the distribution and cardiovascular outcomes according to BMI and waist circumference (WC) of the newly diagnosed heart failure (HF) patients in the entire population of the Republic of Korea for 10 years.
Joongmin Kim, Sungyoun Chun, Jong‐Kwan Park, Hancheol Lee, Ji‐Yong Jang, Hyeongsoo Kim, Geunhee Park, Seung‐Jin Oh, Se‐Jung Yoon   +8 more
wiley   +1 more source

Observations on Angina Pectoris during Drug Treatment of Hypertension [PDF]

, 1956
Walter E. Judson, William Hollander, Robert W. Wilkins   +2 more
openalex   +1 more source